<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758650</url>
  </required_header>
  <id_info>
    <org_study_id>UZBRU_VHH2_2</org_study_id>
    <secondary_id>2020-002483-31</secondary_id>
    <nct_id>NCT04758650</nct_id>
  </id_info>
  <brief_title>Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions and Cardiovascular Atherosclerosis.</brief_title>
  <acronym>MITRAS</acronym>
  <official_title>Phase II Study to Evaluate the Clinical Potential of 68GaNOTA-Anti-MMR-VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Oncological Lesions and Cardiovascular Atherosclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitair Ziekenhuis Brussel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitair Ziekenhuis Brussel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo&#xD;
      imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron&#xD;
      Emission Tomography (PET) in patients with oncological lesions in need of non-surgical&#xD;
      therapy and patients with cardiovascular atherosclerosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">January 26, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 26, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation of uptake of 68GaNOTA-Anti-MMR-VHH2 before start of treatment in HNSCC lesions with time to treatment failure after radiotherapy or systemic treatment including immune checkpoint inhibition. (cohort 1)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Uptake will be measured in cancer lesions on PET/CT 1. Treatment response will be evaluated by assessing time to treatment failure and by assessment of status of patients for treatment failure (Y/N) at 6 months and 12 months after start of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of uptake of 68GaNOTA-Anti-MMR-VHH2 before start of treatment in solid cancer lesions with time to treatment failure after systemic treatment with immune checkpoint inhibition, either or not combined with other systemic therapies. (cohort 2)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Uptake will be measured in cancer lesions on PET/CT 1. Treatment response will be evaluated by assessing time to treatment failure and by assessment of status of patients for treatment failure (Y/N) at 6 months and 12 months after start of treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation of uptake of 68GaNOTA-Anti-MMR-VHH2 in atherosclerotic carotid plaques before surgery with the immunohistological MMR-staining of the excised atherosclerotic carotid plaque. (cohort 3)</measure>
    <time_frame>Resection of lesion up to 21 days after PET/CT</time_frame>
    <description>PET/CT and immunohistochemistry will be assessed using a semi-quantitive scale.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Squamous Cell Carcinoma of Head and Neck</condition>
  <condition>Cancer</condition>
  <condition>Carotid Stenosis</condition>
  <condition>Atherosclerosis of Artery</condition>
  <arm_group>
    <arm_group_label>Head and neck cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with pathology-proven squamous cell carcinomas of the head and neck in need of a non-surgical therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Immune checkpoint inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with any malignancy with a solid component in need of immune checkpoint inhibitor-type immunotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carotid plaque</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with carotid plaque, planned for standard of care carotid endarterectomy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68GaNOTA-Anti-MMR-VHH2</intervention_name>
    <description>All subjects will receive at least one single intravenous injection of the IMP followed by a total body PET/CT prior to receiving standard-of-care therapy.</description>
    <arm_group_label>Carotid plaque</arm_group_label>
    <arm_group_label>Head and neck cancer</arm_group_label>
    <arm_group_label>Immune checkpoint inhibition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>68GaNOTA-Anti-MMR-VHH2</intervention_name>
    <description>An optional injection of the IMP during or after therapy can be administered if a patient is treated with non-surgical modalities.</description>
    <arm_group_label>Head and neck cancer</arm_group_label>
    <arm_group_label>Immune checkpoint inhibition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        COHORT SPECIFIC INCLUSION CRITERIA:&#xD;
&#xD;
          -  COHORT 1:&#xD;
&#xD;
               -  Patients who have given informed consent&#xD;
&#xD;
               -  Patients at least 18 years old&#xD;
&#xD;
               -  Patients diagnosed with biopsy-proven squamous cell carcinomas of the head and&#xD;
                  neck, independent of tumour stage.&#xD;
&#xD;
               -  In order to be eligible, a new non-surgical therapeutic approach should be&#xD;
                  considered by the treating physician(s).&#xD;
&#xD;
               -  In order to minimize partial volume effect, the diameter of at least 1 tumour&#xD;
                  lesion should be ≥ 10 mm in short axis for invaded adenopathies and ≥ 10 mm in&#xD;
                  long axis for all other types of lesions.&#xD;
&#xD;
               -  Patients who already participated in the trial and who are diagnosed with&#xD;
                  progressive or recurrent disease can be re-included if all inclusion criteria and&#xD;
                  none of the exclusion criteria apply.&#xD;
&#xD;
          -  COHORT 2:&#xD;
&#xD;
               -  Patients who have given informed consent&#xD;
&#xD;
               -  Patients at least 18 years old&#xD;
&#xD;
               -  Patient with a biopsy proven local, locally advanced or metastatic malignancy&#xD;
                  with a solid component that is at least ≥ 10 mm in short axis for invaded&#xD;
                  adenopathies and ≥ 10 mm in long axis for all other types of lesions.&#xD;
&#xD;
               -  The patient is planned for immune checkpoint inhibition treatment, either or not&#xD;
                  combined with other systemic therapies.&#xD;
&#xD;
               -  Patients who already participated in the trial and who are diagnosed with&#xD;
                  progressive or recurrent disease can be re-included if all inclusion criteria and&#xD;
                  none of the exclusion criteria apply&#xD;
&#xD;
          -  COHORT 3:&#xD;
&#xD;
               -  Patients who have given informed consent&#xD;
&#xD;
               -  Patients at least 18 years old&#xD;
&#xD;
               -  Patient is planned for the surgical removal of an atherosclerotic plaque of the&#xD;
                  carotid artery, consisting of endarterectomy.&#xD;
&#xD;
        GENERAL EXCLUSION CRITERIA:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher.&#xD;
&#xD;
          -  Pregnant patients.&#xD;
&#xD;
          -  Breast feeding patients.&#xD;
&#xD;
          -  Patients with any serious active infection.&#xD;
&#xD;
          -  Patients who have any other life-threatening illness or organ system dysfunction,&#xD;
             which in the opinion of the investigator would either compromise patient safety or&#xD;
             interfere with the evaluation of the safety of the test radiopharmaceutical.&#xD;
&#xD;
          -  Patients who cannot communicate reliably with the investigator.&#xD;
&#xD;
          -  Patients who are unlikely to cooperate with the requirements of the study.&#xD;
&#xD;
          -  Patients who are unwilling and/or unable to give informed consent.&#xD;
&#xD;
          -  Patients at increased risk of death from a pre-existing concurrent illness.&#xD;
&#xD;
          -  When a patient exhibits symptoms correlated with SARS-CoV-2, the patient should be&#xD;
             tested using the standard of care testing protocol, prior to inclusion. When the test&#xD;
             results indicate an active SARS-CoV-2-infection, the patient is excluded for this&#xD;
             trial.&#xD;
&#xD;
        COHORT SPECIFIC EXCLUSION CRITERIA&#xD;
&#xD;
          -  COHORT 1&#xD;
&#xD;
               -  Patients planned for a surgical resection of the tumour.&#xD;
&#xD;
               -  Patients with recent (&lt; 1 week) gastrointestinal disorders (CTCAE v5.0 grade 3 or&#xD;
                  4) with diarrhoea as major symptom.&#xD;
&#xD;
          -  COHORT 2&#xD;
&#xD;
               -  Patients with recent (&lt; 1 week) gastrointestinal disorders (CTCAE v5.0 grade 3 or&#xD;
                  4) with diarrhoea as major symptom.&#xD;
&#xD;
               -  Patients diagnosed with squamous cell carcinomas of the head and neck. These&#xD;
                  patients can be included into Cohort I.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marleen Keyaerts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitair Ziekenhuis Brussel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UZ Brussel</last_name>
    <phone>+3224776013</phone>
    <email>nucgmail@uzbrussel.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uz Brussel</name>
      <address>
        <city>Brussels</city>
        <state>Brussel</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>UZ BRUSSEL</last_name>
      <phone>+3224776013</phone>
      <email>nucgmail@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>MARLEEN KEYAERTS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 12, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Carotid Stenosis</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

